CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 2, 2012, Pages 213-219

  Lewden, Charlotte ^a,b   Gabillard, Delphine ^a,b   Minga, Albert ^b,c   Ekouévi, Didier K ^a,b,c   Avit, Divine ^d   Konate, Issouf ^e   Amani Bossé, Clarisse ^d   Messou, Eugéne ^c   Coffie, Patrick ^b,c   Ouedraogo, Abdoulaye ^e   Laurent, Christian ^f   Anglaret, Xavier ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Programme PAC CI   (Côte d’Ivoire)

^d ACONDA   (Côte d’Ivoire)

^e CENTRE MURAZ   (Burkina Faso)

^f INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

Adults; CD4 lymphocyte count; HIV infection; Informative censoring; Lost to follow up; Mortality; Sub Saharan Africa

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA; ARTICLE; BURKINA FASO; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COTE D'IVOIRE; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ADULT; AFRICA, WESTERN; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; YOUNG ADULT;

EID: 84857030868     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823b837e     Document Type: Article

References (35)

1. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126: 946-954. (Pubitemid 27255797)
2. Anglaret X, Messou E, Oaussa T, et al. Pattern of bacterial disease in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis, Abidjan, Côte d'Ivoire. AIDS. 2003; 17: 575-584. (Pubitemid 36293111)
3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010. Available at: http://www.who.int/hiv/pub/arv/adult2010/en/index. html. Accessed October 25, 2010.
4. European AIDS Clinical Society. Guidelines clinical management and treatment of HIV-infected adults in Europe Version 5-4. 2011. Available at: http://www.europeanaidsclinicalsociety.org/images/stories/EACSPdf/ 1-treatment-of-hiv-infected-adults.pdf. Accessed July 08, 2011.
5. Grinsztejn B, Ribaudo H, Cohen MS, et al. Effects of early versus delayed initiation of antiretroviral therapy (ART) on HIV clinical outcomes: results from the HPTN 052 randomized clinical trial. Presented at: Proceedings of the 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; July 17-20, 2011; Roma, Italy. [MOAX0105].
6. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010; 304: 321-333.
7. University of Minnesota Clinical and Translational Science Institute. Strategic timing of antiretroviral treatment (START). Available at: http://clinicaltrials.gov/ct2/show/NCT00867048?term=start&rank=1. Accessed May 05, 2011.
8. French National Agency for Research on AIDS and Viral Hepatitis. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). Available at: http://clinicaltrials.gov/ct2/show/NCT00495651?term= temprano&rank=1. Accessed May 05, 2011.
9. When to Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009; 373: 1352-1363.
10. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360: 1815-1826.
11. Shepherd BE, Jenkins CA, Rebeiro PF, et al. Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Epidemiology. 2010; 21: 698-705.
12. The UK Collaborative HIV Cohort (CHIC) Study Steering Committee. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naïve individuals with high CD4 cell count. AIDS. 2007; 21: 1717-1721.
13. Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis. 2008; 197: 398-404. (Pubitemid 351263421)
14. Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients. Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per mL in Europe and North America: a pooled cohort observational study. Lancet. 2010; 376: 340-345.
15. CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS. 2004; 18: 51-58.
16. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet. 2006; 368: 1254-1259. (Pubitemid 44508698)
17. Hargrove JW, Humphrey JH. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS. 2010; 24: F11-F14.
18. Thiebaut R, Jacqmin-Gadda H, Babiker A, et al. Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection. Stat Med. 2005; 24: 65-82. (Pubitemid 40074065)
19. Guo X, Carlin B. Separate and joint modeling for longitudinal and event time data using standard computer packages. Am Stat. 2004; 58: 1-9.
20. Minga A, Danel C, Abo Y, et al. Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote d'Ivoire. Bull World Health Organ. 2007; 85: 116-123. (Pubitemid 46203941)
21. Nagot N, Ouangre A, Ouedraogo A, et al. Spectrum of commercial sex activity in Burkina Faso: classification model and risk of exposure to HIV. J Acquir Immune Defic Syndr. 2002; 29: 517-521. (Pubitemid 34456344)
22. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005; 19: 309-318. (Pubitemid 40396563)
23. Tonwe-Gold B, Ekouevi DK, Bosse CA, et al. Implementing familyfocused HIV care and treatment: the first 2 years' experience of the mother-to-child transmission-plus program in Abidjan, Cote d'Ivoire. Trop Med Int Health. 2009; 14: 204-212.
24. Bartlett JA, Shao JF. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis. 2009; 9: 637-649.
25. Wools-Kaloustian K, Kimaiyo S, Musick B, et al. The impact of the President's Emergency Plan for AIDS Relief on expansion of HIV care services for adult patients in western Kenya. AIDS. 2009; 23: 195-201.
26. Geng EH, Nash D, Kambugu A, et al. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010; 7: 234-244.
27. Rosen S, Fox MP. Retention in HIV Care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011; 8: e1001056.
28. Tayler-Smith K, Zachariah R, Massaquoi M, et al. Unacceptable attrition among WHO stages 1 and 2 patients in a hospital-based setting in rural Malawi: can we retain such patients within the general health system? Trans R Soc Trop Med Hyg. 2010; 104: 313-319.
29. Ekouevi DK, Balestre E, Ba-Gomis FO, et al. Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health. 2010; 15(suppl 1): 34-42.
30. Fox MP, Brennan A, Maskew M, et al. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010; 15: 405-413.
31. Lessells RJ, Mutevedzi PC, Cooke GS, et al. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2011; 56: E79-E86.
32. Anglaret X, Toure S, Gourvellec G, et al. Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from sub-Saharan Africa. J Acquir Immune Defic Syndr. 2004; 35: 320-323. (Pubitemid 38280660)
33. Duvignac J, Anglaret X, Kpozehouen A, et al. CD4+ T-lymphocytes natural decrease in HAART-naive HIV-infected adults in Abidjan. HIV Clin Trials. 2008; 9: 26-35. (Pubitemid 351214238)
34. Brinkhof MW, Spycher BD, Yiannoutsos C, et al. Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS One. 2010; 5: e14149.
35. Ekouevi DK, Inwoley A, Tonwe-Gold B, et al. Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings. AIDS Res Hum Retroviruses. 2007; 23: 1469-1474.